<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Animals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Animals (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2763</journal-id><journal-id journal-id-type="pmc-domain">animals</journal-id><journal-id journal-id-type="publisher-id">animals</journal-id><journal-title-group><journal-title>Animals : an Open Access Journal from MDPI</journal-title></journal-title-group><issn pub-type="epub">2076-2615</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11762997</article-id><article-id pub-id-type="pmcid-ver">PMC11762997.1</article-id><article-id pub-id-type="pmcaid">11762997</article-id><article-id pub-id-type="pmcaiid">11762997</article-id><article-id pub-id-type="pmid">39858287</article-id><article-id pub-id-type="doi">10.3390/ani15020287</article-id><article-id pub-id-type="publisher-id">animals-15-00287</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Tumor-Infiltrating Lymphocytes and Neutrophils and Their Location in Canine Mammary Neoplasms with a Solid Arrangement: A Prognostic Factor?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8403-538X</contrib-id><name name-style="western"><surname>Flecher</surname><given-names initials="MC">Mayra C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-animals-15-00287" ref-type="aff">1</xref><xref rid="af2-animals-15-00287" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1642-6957</contrib-id><name name-style="western"><surname>Reys</surname><given-names initials="MP">Marina P.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-animals-15-00287" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3077-7526</contrib-id><name name-style="western"><surname>Balabram</surname><given-names initials="D">D&#233;bora</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af3-animals-15-00287" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0662-9577</contrib-id><name name-style="western"><surname>Nakagaki</surname><given-names initials="KYR">Karen Y. R.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-animals-15-00287" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5650-6743</contrib-id><name name-style="western"><surname>Cassali</surname><given-names initials="GD">Geovanni D.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-animals-15-00287" ref-type="aff">1</xref><xref rid="c1-animals-15-00287" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Zuccari</surname><given-names initials="DAPDC">Debora Aparecida Pires de Campos</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Chuffa</surname><given-names initials="LGDA">Luiz Gustavo de Almeida</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Tamarindo</surname><given-names initials="GH">Guilherme Henrique</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-animals-15-00287"><label>1</label>Department of General Pathology, Laboratory of Comparative Pathology, Federal University of Minas Gerais, Belo Horizonte 31270-091, Minas Gerais, Brazil; <email>mayraflecher@gmail.com</email> (M.C.F.); <email>marinareys13@gmail.com</email> (M.P.R.); <email>karenyumi@ymail.com</email> (K.Y.R.N.)</aff><aff id="af2-animals-15-00287"><label>2</label>Department of Veterinary Medicine, Universidade Vila Velha, Vila Velha 29102-920, Esp&#237;rito Santo, Brazil</aff><aff id="af3-animals-15-00287"><label>3</label>Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 31270-091, Minas Gerais, Brazil</aff><author-notes><corresp id="c1-animals-15-00287"><label>*</label>Correspondence: <email>cassalig@icb.ufmg.br</email>; Tel.: +55-31-34092883</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><volume>15</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">480386</issue-id><elocation-id>287</elocation-id><history><date date-type="received"><day>12</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>14</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-29 08:25:14.007"><day>29</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="animals-15-00287.pdf"/><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>Mammary neoplasms are the most common tumors in female dogs, and mammary neoplasms with a solid arrangement encompass histological types with high proliferative activity that commonly lead to metastasis. In human breast tumors, in addition to the histological type, the characterization of the inflammatory infiltrate and its location are considered prognostic and predictive factors. In veterinary medicine, little is still known about the influence of inflammation on cancer progression and its relationship with histological types. In the present study, we observed that neoplasms with a solid arrangement presenting with a high density of lymphocytes and neutrophils, especially in the intratumoral area, are associated with shorter survival time, and that the density of intratumoral B lymphocytes is proportional to the presence of lymph node metastasis. Therefore, tumor inflammation should be considered as a factor influencing the progression of mammary neoplasms in female dogs.</p></abstract><abstract><title>Abstract</title><p>In canine mammary neoplasms, greater inflammation is associated with higher histological grade, lymphatic invasion, and metastases. This retrospective study assessed the density of peri- and intratumoral tumor-infiltrating lymphocytes (TILs), tumor-associated neutrophils (TANs), and CD3<sup>+</sup> and CD79<sup>+</sup> lymphocytes in canine mammary neoplasms with a solid arrangement, and associated such data with histological types, immunophenotype, prognostic factors, cyclooxygenase-2 (Cox-2) expression and overall and cancer-specific survival. Sixty-one neoplasms with a solid arrangement were classified as malignant myoepitheliomas (6/9.8%), solid papillary carcinomas (8/13.1%), carcinomas with a solid pattern (9/14.8%), basaloid carcinomas (BC) (19/31.1%), and malignant adenomyoepitheliomas (19/31.1%). Intra- and peritumoral TILs, TANs, and TCD3<sup>+</sup> and BCD79<sup>+</sup> lymphocytes were counted, and based on the resulting median, the neoplasms were divided into low or high cell infiltration. BCs had the lowest density of intratumoral TILs (<italic toggle="yes">p</italic> = 0.02), and luminal B neoplasms showed a significantly higher density of intratumoral TCD3<sup>+</sup> than luminal A cases. Neoplasms with a higher density of peritumoral CD3<sup>+</sup> and CD79<sup>+</sup> had significantly greater proliferative activity. High infiltration of intratumoral BCD79<sup>+</sup> lymphocytes was related to nodal metastasis (<italic toggle="yes">p</italic> = 0.03). Intratumoral TILs and TCD3<sup>+</sup> were associated with shorter survival time. Therefore, intratumoral lymphocyte infiltration is possibly an important feature in the progression of cancer and influences the survival in bitches with solid arrangement neoplasms.</p></abstract><kwd-group><kwd>mammary neoplasms</kwd><kwd>tumor-infiltrating lymphocytes</kwd><kwd>survival analysis</kwd><kwd>CD3</kwd><kwd>CD79</kwd><kwd>neutrophils</kwd><kwd>metastasis</kwd><kwd>dogs</kwd></kwd-group><funding-group><award-group><funding-source>National Council for Scientific and Technological Development (CNPq)</funding-source></award-group><award-group><funding-source>Minas Gerais Research Foundation&#8212;FAPEMIG</funding-source></award-group><award-group><funding-source>Minas Gerais Network for Translational Research in Immunobiologicals and Biopharmaceuticals in Cancer</funding-source><award-id>RED-00031-21</award-id></award-group><award-group><funding-source>Coordination for Personal Improvement of Higher Education (CAPES), Brazil</funding-source></award-group><funding-statement>This study was funded by the National Council for Scientific and Technological Development (CNPq), the Minas Gerais Research Foundation&#8212;FAPEMIG, the Minas Gerais Network for Translational Research in Immunobiologicals and Biopharmaceuticals in Cancer (REMITRIBIC, RED-00031-21), and the Coordination for Personal Improvement of Higher Education (CAPES), Brazil.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-animals-15-00287"><title>1. Introduction</title><p>The characterization of tumor microenvironment through the evaluation of infiltrating leukocytes is already established for some types of neoplasms in the human species, such as colorectal carcinomas [<xref rid="B1-animals-15-00287" ref-type="bibr">1</xref>,<xref rid="B2-animals-15-00287" ref-type="bibr">2</xref>,<xref rid="B3-animals-15-00287" ref-type="bibr">3</xref>], oral and cutaneous squamous cell tumors [<xref rid="B4-animals-15-00287" ref-type="bibr">4</xref>,<xref rid="B5-animals-15-00287" ref-type="bibr">5</xref>], renal, head and neck, hepatocellular, pancreatic tumors [<xref rid="B6-animals-15-00287" ref-type="bibr">6</xref>], and mammary [<xref rid="B7-animals-15-00287" ref-type="bibr">7</xref>,<xref rid="B8-animals-15-00287" ref-type="bibr">8</xref>] and urothelial bladder cell tumors [<xref rid="B9-animals-15-00287" ref-type="bibr">9</xref>].</p><p>The presence of tumor-infiltrating lymphocytes (TILs) and their subtypes is associated with morphological (histological grade, size, pleomorphism, and mitotic count) and immunophenotypic characteristics of breast tumors. Thus, TILs are considered prognostic and predictive factors in women&#8217;s breast cancers [<xref rid="B10-animals-15-00287" ref-type="bibr">10</xref>,<xref rid="B11-animals-15-00287" ref-type="bibr">11</xref>,<xref rid="B12-animals-15-00287" ref-type="bibr">12</xref>,<xref rid="B13-animals-15-00287" ref-type="bibr">13</xref>]. In women, TILs tend to be present in a greater proportion in neoplasms without the expression of hormone receptors and show an overexpression of HER-2 and a higher percentage of Ki-67 [<xref rid="B14-animals-15-00287" ref-type="bibr">14</xref>,<xref rid="B15-animals-15-00287" ref-type="bibr">15</xref>,<xref rid="B16-animals-15-00287" ref-type="bibr">16</xref>]. Also, greater inflammation in triple-negative neoplasms (TN) and tumors with HER-2 overexpression, especially in the intratumoral area, is associated with a better response to chemotherapy treatment [<xref rid="B10-animals-15-00287" ref-type="bibr">10</xref>,<xref rid="B13-animals-15-00287" ref-type="bibr">13</xref>,<xref rid="B14-animals-15-00287" ref-type="bibr">14</xref>]. In female dogs, the highest intensity of TILs is observed in higher histologic grade neoplasms, with lymphatic invasion [<xref rid="B16-animals-15-00287" ref-type="bibr">16</xref>,<xref rid="B17-animals-15-00287" ref-type="bibr">17</xref>] and shorter survival time, a characteristic that is considered an independent prognostic factor. In addition, the highest percentage of B cells (CD79<sup>+</sup>) was seen in carcinoma in mixed tumors with metastasis to lymph nodes when compared to carcinoma in mixed tumors without metastasis to lymph nodes [<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>]. However, little is known about the influence of inflammation and the relationship of inflammation and immunophenotypes in mammary neoplasms in female dogs. No relationship was found between TIL and molecular subtypes in one study [<xref rid="B16-animals-15-00287" ref-type="bibr">16</xref>], but in another, the peritumoral inflammation was shown as an independent prognostic factor for bitches with triple-negative tumors [<xref rid="B19-animals-15-00287" ref-type="bibr">19</xref>].</p><p>Few studies approach tumor-associated neutrophils (TANs) in women breast cancer, and most of those studies are conducted in vitro and in animal models. Similarly to lymphocytes, neutrophils may be associated with a longer or shorter survival time, depending on the type of cytokine or receptors present in the microenvironment, [<xref rid="B20-animals-15-00287" ref-type="bibr">20</xref>,<xref rid="B21-animals-15-00287" ref-type="bibr">21</xref>]. Estrogen receptor-positive neoplasms, in advanced stages, show an increase in the amount of TGF-&#223; in the microenvironment, favoring the chemotaxis and polarization of N2 neutrophils, which favor neoplastic dissemination and pre-metastatic niche formation [<xref rid="B22-animals-15-00287" ref-type="bibr">22</xref>]. In the few studies involving women, the increase in the average amount of neutrophils is associated with TN- and HER-2-positive tumors [<xref rid="B23-animals-15-00287" ref-type="bibr">23</xref>], and a high density of TANs is associated with shorter disease-free time [<xref rid="B24-animals-15-00287" ref-type="bibr">24</xref>]. In bitches, the amount of neutrophils was higher in carcinoma in mixed tumors and tubular carcinomas compared to solid carcinomas and benign mixed tumors [<xref rid="B25-animals-15-00287" ref-type="bibr">25</xref>].</p><p>Although the quantification of TILs in H&amp;E slides is an important parameter and is associated with prognostic and predictive factors in breast cancer in women, it is not enough to identify lymphocyte subtypes, which are fundamental for understanding the immune response to cancer. In the present study, we quantified tumor-infiltrating lymphocytes (TILs) and tumor-associated neutrophils (TANs) in the peri- and intratumoral areas, on H&amp;E slides, and on slides with immunohistochemistry for CD3<sup>+</sup> and CD79<sup>+</sup> lymphocytes. Afterwards, we dichotomized high- and low-density inflammations to associate them with the histological types of neoplasms with a solid arrangement, immunophenotypes, prognostic factors (tumor size, regional lymph node metastasis, Ki-67 index, and mitotic count), Cox-2 immunostaining, and overall and specific survival time for bitches.</p></sec><sec id="sec2-animals-15-00287"><title>2. Material and Methods</title><sec id="sec2dot1-animals-15-00287"><title>2.1. Selection and Classification of Samples and Clinical Follow-Up</title><p>The criteria for sample selection, classification of neoplasms, and clinical follow-up of the animals were based on previous study, which included 65 samples [<xref rid="B26-animals-15-00287" ref-type="bibr">26</xref>]. However, four samples were entirely used up in the first part of the research, and in the present article, 61 of these samples were used. The sixty-one canine mammary neoplasms with a solid arrangement, diagnosed between 2011 and 2022, were selected from the collections of the Comparative Pathology Laboratory at the Institute of Biological Sciences of the Federal University of Minas Gerais (UFMG), the Pathology Laboratory of Vila Velha University (UVV), the Celulavet Laboratory, and the Center for Research in Mammary Oncology at the Federal University of Bahia (UFBA). Only samples from female dogs previously diagnosed with neoplasms classified as solid carcinoma [<xref rid="B27-animals-15-00287" ref-type="bibr">27</xref>] or basaloid carcinoma [<xref rid="B28-animals-15-00287" ref-type="bibr">28</xref>], for which presented macroscopic description information of location and size of neoplasms was available and evaluation of regional lymph nodes was performed, were included. Female dogs presenting with other histological types of more aggressive mammary-origin neoplasms associated with shorter survival times [<xref rid="B28-animals-15-00287" ref-type="bibr">28</xref>,<xref rid="B29-animals-15-00287" ref-type="bibr">29</xref>], non-mammary malignant neoplasms, and those that had been treated prior to surgery were excluded from the study.</p><p>From these criteria, histological slides stained by hematoxylin and eosin (H&amp;E) were re-evaluated by two veterinary pathologists (GDC&#8212;board-certified by the Brazilian Association of Veterinary Pathology, MCF&#8212;residency in Veterinary Pathology and Ph.D. in Pathology) and reclassified into carcinomas with a solid pattern (CSP), basaloid carcinomas (BC), solid papillary carcinomas (SPC), malignant adenomyoepitheliomas (MAME), and malignant myoepitheliomas (MME) based on morphological and phenotypic patterns (<xref rid="app1-animals-15-00287" ref-type="app">Figure S1</xref>) [<xref rid="B30-animals-15-00287" ref-type="bibr">30</xref>]. Neuroendocrine carcinomas were not evaluated in the present study due to the small number of samples. MAME may present benign epithelial areas, making it difficult to assess its epithelial invasion area, and MM is composed of more than 90% myoepithelial tissue [<xref rid="B30-animals-15-00287" ref-type="bibr">30</xref>]. Therefore, as these histological types do not fit the standardization of histological grading used for invasive carcinomas [<xref rid="B31-animals-15-00287" ref-type="bibr">31</xref>], grading was not evaluated in this study. In all 61 cases, the regional lymph nodes were also evaluated for the detection of metastasis. Information on neoplasm size was provided by the laboratory where the samples came from, and tumor size was stratified into T1 (&lt; 3 cm), T2 (between 3 and 5 cm), and T3 (&gt; 5 cm), following the TNM system [<xref rid="B32-animals-15-00287" ref-type="bibr">32</xref>]. For neoplasms larger than T2, more than one histological slide was evaluated; the slide containing the best sample of approximately 2.0 cm with less necrosis and fixation and crushing artifacts was selected. As utilized in the grading system by Elston and Ellis, mitotic counting was performed in 10 fields (2.37 mm<sup>2</sup>) at the tumor periphery in continuous fields. As information on distant metastasis assessment was incomplete, the complete staging was not performed in the present study.</p><p>The time in days from the date of surgery until the death of the dog from any cause and from neoplasia-related cause was calculated for overall survival and specific survival, respectively [<xref rid="B17-animals-15-00287" ref-type="bibr">17</xref>,<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>,<xref rid="B19-animals-15-00287" ref-type="bibr">19</xref>]. Cause of death related to neoplasia means spontaneous death or euthanasia due to local progression or systemic deterioration in animals with metastatic disease. The follow-up was carried out for a period of at least one year. Information was obtained from the responsible tutor and/or the veterinary clinician.</p></sec><sec id="sec2dot2-animals-15-00287"><title>2.2. Immunohistochemistry</title><p>Four-micrometer-thick sections were obtained from the paraffin blocks and placed on gelatinized slides, submitted to deparaffinization, dehydration in alcohol and xylol, and manual staining for the markers following previously validated protocols [<xref rid="B26-animals-15-00287" ref-type="bibr">26</xref>,<xref rid="B30-animals-15-00287" ref-type="bibr">30</xref>,<xref rid="B33-animals-15-00287" ref-type="bibr">33</xref>]. The antigenic recovery was performed in moist heat, within citrate pH 6.0. Novolink<sup>&#174;</sup> kit solution (Leica) was used as the secondary antibody and detection system. Evaluations were performed under an Olympus BX-40 microscope coupled with a Spot Insight Color digital camera and with the aid of SPOT capture software version 3.4.5.</p><p>In order to establish the immunophenotype of the neoplasms, immunohistochemistry was performed for estrogen (ER, ready-to-use, clone Ep1, Dako<sup>&#174;</sup>) and progesterone (PR, 1:50, clone hpra2, Thermo Fisher<sup>&#174;</sup>) receptors, cell proliferation factor Ki-67 (1:50, clone mib 1, Dako<sup>&#174;</sup>), and epidermal growth factor 2 (HER-2, 1:200, clone c erb 2, Thermo Fisher<sup>&#174;</sup>) in all selected samples. Immunolabeling for cyclooxygenase 2 (Cox-2, ready-to-use, clone Sp21, Invitrogen<sup>&#174;</sup>) was also performed on 59 samples. The antibodies are well standardized for the technique used in the laboratory routine, and the antigenic specificity has already been tested, as shown in previous publications [<xref rid="B26-animals-15-00287" ref-type="bibr">26</xref>,<xref rid="B30-animals-15-00287" ref-type="bibr">30</xref>,<xref rid="B33-animals-15-00287" ref-type="bibr">33</xref>]. Due to wear of the paraffin block during the study, two cases lacked enough material for this analysis. For the evaluation of ER and PR labeling, a scoring system considering the number of cells with positive nuclear labeling (negative: &lt;1%, +: 1&#8211;25% of labeled cells; ++: 26&#8211;50% of labeled cells, + ++: 51&#8211;75%; + +++: &gt;75% of labeled cells) was adopted (<xref rid="app1-animals-15-00287" ref-type="app">Figures S2 and S3</xref>) [<xref rid="B34-animals-15-00287" ref-type="bibr">34</xref>]. Ki-67 was determined by the percentage of cells with nuclear staining in a count of 500 cells through photomicrographs made in a 40&#215; (0.096 mm<sup>2</sup>) objective hot spot analyzed with Image J<sup>&#174;</sup> imaging system, and the cutoff point &#8805;20% of labeled cells was used for classification as high and low proliferation (<xref rid="app1-animals-15-00287" ref-type="app">Figure S4</xref>) [<xref rid="B35-animals-15-00287" ref-type="bibr">35</xref>]. HER-2 expression followed the guidelines of membrane marking score, considering scores 0, 1+, and 2+ as negative and 3+ as positive (<xref rid="app1-animals-15-00287" ref-type="app">Figure S5</xref>) [<xref rid="B36-animals-15-00287" ref-type="bibr">36</xref>]. Then, the neoplasms were categorized into luminal A (ER and/or PR positive, HER2 negative, and Ki-67 &lt;20%); luminal B HER2 negative (ER and/or PR positive, HER2 negative, and Ki-67 &#8805;20%), luminal B HER2 positive (ER and/or PR positive, HER2 positive, and any Ki-67), HER2 overexpressed (ER and PR negative, and HER2 positive), and triple negative (TN) (ER, PR, and HER2 negative) [<xref rid="B26-animals-15-00287" ref-type="bibr">26</xref>,<xref rid="B35-animals-15-00287" ref-type="bibr">35</xref>]. Normal mammary gland was used as positive control, while a buffer solution was used as negative control instead of the primary antibody. The Cox-2 assessment was based on a semi-quantitative evaluation of labeled tumor cells in the cytoplasm. Percentage of labeled tumor cells throughout the evaluated fragment (0= absent, 1= less than 10% of cells labeled, 2= 10 to 30% of cells labeled, 3= 31 to 60% of cells labeled, 4= more than 61% of cells labeled) and intensity score (0= absent, 1= weak (+) labeling, 2= moderate (++) labeling, and 3= strong (+ ++) labeling) were defined. The final score is established by multiplying the distribution by intensity (<xref rid="app1-animals-15-00287" ref-type="app">Figure S6</xref>) [<xref rid="B37-animals-15-00287" ref-type="bibr">37</xref>].</p><p>Anti-CD3 (1:200, Dako<sup>&#174;</sup>, A052) antibodies were used for the identification of T cells, while anti-CD79 antibodies were used (1:400, Biolegend<sup>&#174;</sup>, HM47) for the identification of B cells. Normal dog lymph nodes were used as positive and negative controls. A buffer solution was used for negative control instead of the primary antibody. The negative control was prepared following the same technique described in the determination of immunophenotypes.</p></sec><sec id="sec2dot3-animals-15-00287"><title>2.3. Characterization of the Infiltrate in Histological Slides and Immunohistochemistry</title><p>Images of eight hot spots at 600&#215; (60&#215; objective and 10&#215; ocular) were captured from the H&amp;E slides and contained a fragment of each neoplasm for quantification of TILs and TANs in the peri- and intratumoral areas, separately. The 600&#215; magnification (0.087 mm<sup>2</sup>) provides better definition of the cell types. Hot spot stands for the field of the fragment that presents a higher concentration of inflammatory cells. For the quantification of T and B cells labeled for CD3<sup>+</sup> and CD79<sup>+</sup>, images of eight hot spots were captured at 400&#215; (0.196 mm<sup>2</sup>), following the same capture methodology made on the H&amp;E slides. Photomicrographs were taken by a Spot Insight Color digital camera adapted on the Olympus BX-40 microscope with the aid of SPOT capture software version 3.4.5 [<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>].</p><p>The identification of inflammatory cells (neutrophils and lymphocytes) on the histological slides was based on the morphological aspect of each cell. In the slides submitted to immunolabeling, lymphocytes were positive when the label was identified in the cytoplasm in a diffuse or granular way (nuclear labeling was not considered).</p><p>Inflammatory cells (lymphocytes, their subtypes, and neutrophils) were counted separately in the peritumoral area (in the capsule or connective tissue around the neoplasm) and intratumoral area (in the stroma between the neoplastic lobes and in direct contact with the tumor cells) in the eight photographed hot spots of each sample. Finally, the number of each type of inflammatory cell, in the respective areas, was summed separately for each neoplasm, and the cutoff point to characterize how high and low density of inflammatory infiltrate was based on the median value of each cell in the study population. From the total number of cells, neutrophil/lymphocyte (N/L) and CD79<sup>+</sup>/CD3<sup>+</sup> lymphocyte ratios were calculated, and the median also served as a cutoff point to separate the samples with high and low expression of inflammatory cells.</p><p>All procedures performed in the present study followed the ethical principles for the use of animals in experimentation. The project was approved by the ethics committee on the use of animals (CEUA-UFMG, no. 11/2017).</p></sec><sec id="sec2dot4-animals-15-00287"><title>2.4. Statistics</title><p>GraphPad Prism software version 8.2 was used for the statistical analysis. Continuous variables (mitotic count and Ki-67 expression) had their normality verified by the Kolmogorov&#8211;Smirnov&#8217;s test, and the association with the density of inflammatory infiltrate was made by the Mann&#8211;Whitney test. For comparison of inflammatory cell infiltrate between different areas on the same tumor, the Wilcoxon test was chosen. Fisher&#8217;s exact test was used to analyze the association between qualitative variables (histological types, immunophenotypes, tumor size, presence of lymph node metastasis, and Cox-2 expression) and intensity of inflammation. In all cases, <italic toggle="yes">p</italic> &lt; 0.05 was considered significant. The analysis of overall and specific survival was made by Kaplan&#8211;Meier curves and the long-rank test provided the comparison between curves. For the analysis of survival in relation to inflammatory density, the density of each cell type (high and low) was compared between peritumoral and intratumoral areas. Survival was also associated with N/L and CD3<sup>+</sup>/CD79<sup>+</sup> lymphocyte ratios. The Cox regression model was performed in Jamovi version 2.3.28 for univariate and multivariate analysis, considering variables whose significance was previously established in the survival test by Kaplan&#8211;Meier.</p></sec></sec><sec sec-type="results" id="sec3-animals-15-00287"><title>3. Results</title><p>Sixty-one neoplasms with a solid arrangement were analyzed: six (9.8%) malignant myoepitheliomas, eight (13.1%) solid papillary carcinomas, nine (14.8%) carcinomas with a solid pattern, nineteen (31.1%) basaloid carcinomas, and nineteen (31.1%) malignant adenomyoepitheliomas. As for immunophenotypes, 13 neoplasms (21.3%) were luminal A, 42 (68.9%) were luminal B HER-2 negative, and 6 (9.8%) were luminal B HER-2 positive. None of the neoplasms were TN or HER-2 overexpressed.</p><p>The ages of the animals in the study ranged from 3 to 19 years old, with a mean age of 11 years old (standard deviation 3.3). The majority were mixed-breed animals (18/61, 29.5%), followed by poodles (16/61, 26.23%), Yorkshire terriers (4/61, 6.56%), and German shepherds and Shih tzus with the same amount (3/61, 4.92%). Other breeds in smaller numbers included dachshunds, French bulldogs, Akitas, Maltese, Rottweilers, and Beagles.</p><p>In the quantitative analysis on HE slides, the total number of lymphocytes was significantly higher than that of neutrophils (<italic toggle="yes">p</italic> = 0.003). Most neoplasms, 44/61 (72.1%), presented a greater number of lymphocytes in the peritumoral area than in the intratumoral area (<italic toggle="yes">p</italic> = 0.0001). This was also observed for neutrophils, with infiltration in the peritumoral area being greater than in the intratumoral area in 45/61 samples (73.8%) (<italic toggle="yes">p</italic> = 0.02).</p><p>In the count of lymphocyte subtypes after immunostaining for CD3<sup>+</sup> and CD79<sup>+</sup>, 57 of 61 (93.4%) neoplastic samples showed greater infiltration of total TCD3<sup>+</sup> cells when compared to BCD79<sup>+</sup> cells, which was higher in only 4/61(6.6%) samples (<italic toggle="yes">p</italic> = 0.0001). Regarding the location of the infiltrate of TCD3<sup>+</sup> cells, 37/61 (60.7%) neoplasms presented a higher amount of those cells in the intratumoral area compared to the peritumoral area, but no significant difference was seen (<italic toggle="yes">p</italic> = 0.20). Meanwhile, BCD79<sup>+</sup> cells were in significantly higher number in the peritumoral area in 47/61 (77.3%) neoplasms than in the intratumoral area (<italic toggle="yes">p</italic> = 0.02).</p><p>Median and standard deviation values of each cell type are shown in <xref rid="animals-15-00287-t001" ref-type="table">Table 1</xref>. <xref rid="animals-15-00287-t002" ref-type="table">Table 2</xref> and <xref rid="animals-15-00287-t003" ref-type="table">Table 3</xref> contain the morphological and immunophenotypic characteristics of the infiltrate in each subtype of neoplasms.</p><sec id="sec3dot1-animals-15-00287"><title>3.1. Association Between Inflammatory Infiltrate in Relation to Subtypes and Immunophenotypes of Solid Neoplasms</title><p>In the evaluation of TILs, most CSP (6/66.7%), SPC (6/75%), MME (4/66.7%), and MAME (12/63.2%) neoplasms showed a significantly higher density of TILs in the intratumoral area when compared to BC tumors, among which only 4/21.1% neoplasms presented a high density of TILs (<italic toggle="yes">p</italic> = 0.02). In the peritumoral area, no difference in the density of the lymphocyte infiltrate was observed between histological types (<xref rid="animals-15-00287-f001" ref-type="fig">Figure 1</xref>A,B). The density of TANs, TCD3<sup>+</sup>, and BCD79<sup>+</sup> cells in the peri- and intratumoral areas showed no significant differences between histological types (<xref rid="animals-15-00287-t001" ref-type="table">Table 1</xref> and <xref rid="animals-15-00287-t002" ref-type="table">Table 2</xref>). <xref rid="animals-15-00287-f002" ref-type="fig">Figure 2</xref> shows the intensity of cellular infiltration between basaloid carcinoma and carcinoma with a solid pattern.</p><p>Neoplasms with luminal B immunophenotypes (HER-2 negative or positive) showed higher density of intratumoral TCD3<sup>+</sup> lymphocytes when compared to luminal A neoplasms (<italic toggle="yes">p</italic> = 0.04). Only three out of thirteen (23.1%) luminal A neoplasms presented a high infiltration of intratumoral TCD3<sup>+</sup> lymphocytes, while luminal B HER-2 negative or HER-2 positive presented a higher percentage of neoplasms with a high density of this cell type, which were 23/42 (54.8%) and 5/6 (83.3%), respectively. The density of the infiltration of CD79<sup>+</sup> cells (<xref rid="animals-15-00287-f003" ref-type="fig">Figure 3</xref>), as TILs and TANs, and their respective locations showed no significant association with immunophenotypes.</p></sec><sec id="sec3dot2-animals-15-00287"><title>3.2. Association Between Proliferative Rate, Presence of Lymph Node Metastases, and Inflammatory Infiltrate</title><p>Twenty-one female dogs (34.4%) had lymph node metastases. Of these, 16 (76.2%) had a high density of intratumoral BCD79<sup>+</sup> lymphocyte infiltrate (<italic toggle="yes">p</italic> = 0.03). On the other hand, the density of this peritumoral cell was not associated with the presence of metastasis (<italic toggle="yes">p</italic> = 0.59) (<xref rid="animals-15-00287-f004" ref-type="fig">Figure 4</xref>). The density of TANs in the peritumoral area was not statistically significantly associated with lymph node metastases (<italic toggle="yes">p</italic> = 0.05), even though 15 (71.9%) of the 21 neoplasms that metastasized to lymph nodes exhibited a TAN density above the median in the peritumoral area. For TILs and TCD3<sup>+</sup> cells, no significant difference was observed between the density and the site of inflammation and lymph node status.</p><p>Neoplasms with a high density of intratumoral TILs had a higher mitotic count with a median of 20 mitotic figures (2.37 mm<sup>2</sup>), while neoplasms with a low density of TILs had a median of 14 mitotic figures (<italic toggle="yes">p</italic> = 0.03). However, the density of peritumoral TILs was not significantly related to the mitotic count (<italic toggle="yes">p</italic> = 0.05). A high density of peritumoral TCD3<sup>+</sup> and BCD79<sup>+</sup> cells was also associated with a higher mitotic count. Neoplasms with a high infiltration of peritumoral TCD3<sup>+</sup> and BCD79<sup>+</sup> lymphocytes presented a median of 21 mitotic figures, while those with low infiltration presented 13 mitotic figures (<italic toggle="yes">p</italic> = 0.006) for both cell types. Regarding intratumoral infiltration of CD3<sup>+</sup> and CD79<sup>+</sup>, only intratumoral CD79 lymphocyte infiltration was significantly associated with mitotic count (<italic toggle="yes">p</italic> = 0.02). Neoplasms with a high density of those cells had a median of 19 mitotic figures, and those with low infiltration had 12 mitotic figures (<italic toggle="yes">p</italic> = 0.02). The intensities of peri- (<italic toggle="yes">p</italic> = 0.9) and intratumoral (<italic toggle="yes">p</italic> = 0.7) TANs were not associated with mitotic counting.</p><p>When evaluating the density of inflammation with Ki-67 immunostaining, we observed that neoplasms with high TILs (<italic toggle="yes">p</italic> = 0.02) and a high infiltration of TCD3<sup>+</sup> (<italic toggle="yes">p</italic> = 0.007) and BCD79<sup>+</sup> cells (<italic toggle="yes">p</italic> = 0.02) in the peritumoral area were associated with a higher percentage of immunostaining (<xref rid="animals-15-00287-f005" ref-type="fig">Figure 5</xref>). Neoplasms with a high density of TILs and TCD3<sup>+</sup> and BCD79<sup>+</sup> cells had the same median of Ki-67 labeling (34%), and neoplasms with a low intensity of those cells had a median of 26%, 25%, and 26% of immunostaining, respectively. The remaining locations of TILs and CD3<sup>+</sup> and CD79<sup>+</sup> cells, as well as TANs, were not associated with the percentage of Ki-67 labeling.</p></sec><sec id="sec3dot3-animals-15-00287"><title>3.3. Association Between Tumor Size and Cox-2 Immunostaining with Inflammatory Infiltrate</title><p>The results are detailed in <xref rid="animals-15-00287-t001" ref-type="table">Table 1</xref> and <xref rid="animals-15-00287-t002" ref-type="table">Table 2</xref>.</p><p>Among the neoplasms evaluated (<italic toggle="yes">n</italic> = 61), 25 (41%) were classified as T1, 12 (19.7%) as T2, and 24 (39.3%) as T3. No association of tumor size with the density of TILs, TANs, TCD3<sup>+</sup>, and BCD79<sup>+</sup> was observed.</p><p>Of the 59 neoplasms evaluated for Cox-2, only 17 (28.8%) presented positive immunostaining; 16 presented scores up to three, and 1 presented a score of six. No statistical difference was seen between peri- and intratumoral inflammations and Cox-2 positivity.</p></sec><sec id="sec3dot4-animals-15-00287"><title>3.4. Association Between Inflammatory Infiltrate and Survival Time</title><p>Information on overall survival was available for 47/61 (77%) female dogs, of which 35 (74%) died and 12 (26%) were alive at the end of the study. Of the 35 dogs that died, 22 (63%) died from causes related to the mammary tumor. The median overall survival was 365 days (95% CI, 283 to 630 days), and the specific survival was 670 days (95% CI, with a minimum of 365).</p><p>Female dogs who had neoplasms with a high density of intratumoral TANs had shorter median overall survival time than those with a low infiltration of such cells (<italic toggle="yes">p</italic> = 0.04, HR = 2.07, CI: 1.02&#8211;4.21), which were 210 and 425 days of survival, respectively. On the other hand, infiltration with peritumoral TANs (<italic toggle="yes">p</italic> = 0.2) had no influence on survival. Also, overall survival was not associated with TILs in the peri- (<italic toggle="yes">p</italic> = 0.14) and intratumoral (<italic toggle="yes">p</italic> = 0.10) areas, the infiltration of peri- (<italic toggle="yes">p</italic> = 0.48) and intratumoral (<italic toggle="yes">p</italic> = 0.05) TCD3<sup>+</sup> cells, and the infiltration of peri- (<italic toggle="yes">p</italic> = 0.17) and intratumoral (<italic toggle="yes">p</italic> = 0.11) BCD79<sup>+</sup> cells (<xref rid="animals-15-00287-t004" ref-type="table">Table 4</xref>).</p><p>In the specific survival evaluation, 50% of female dogs presenting neoplasms with a high density of intratumoral TILs had died in 395 days, and 64% of those with a low density of TILs were still alive after 1000 days (<italic toggle="yes">p</italic> = 0.02, HR = 2.57, CI:1.11&#8211;5.97). That was also similar to what was observed in the evaluation of TCD3<sup>+</sup> cells, where patients with high intratumoral density showed a median survival time of 365 days, and 61% of those with low intratumoral density were still alive after 1000 days (<italic toggle="yes">p</italic> = 0.01, HR = 2.85, CI:1.23&#8211;5.63). The density of peritumoral TILs (<italic toggle="yes">p</italic> = 0.53) and TCD3<sup>+</sup> (<italic toggle="yes">p</italic> = 0.50), peri- (<italic toggle="yes">p</italic> = 0.11) and intratumoral (<italic toggle="yes">p</italic> = 0.06) BCD79<sup>+</sup> cells, and peri- (<italic toggle="yes">p</italic> = 0.48) and intratumoral TANs (<italic toggle="yes">p</italic> = 0.28) was not associated with dog survival (<xref rid="animals-15-00287-f006" ref-type="fig">Figure 6</xref>; <xref rid="animals-15-00287-t004" ref-type="table">Table 4</xref>).</p><p>The N/L and CD3+/CD79 cell ratios were also unrelated to the overall (<italic toggle="yes">p</italic> = 0.54; <italic toggle="yes">p</italic> = 0.53) and specific (<italic toggle="yes">p</italic> = 0.81, <italic toggle="yes">p</italic> = 0.57) survival time of female dogs.</p><p>In the specific survival analysis by Cox regression, the univariate analysis showed that a high density of intratumoral TILs increases the risk of death related to the neoplasm. The high presence of TILs is associated with a risk ratio of 2.76 times (<italic toggle="yes">p</italic> = 0.03, confidence interval, CI, 95% = 1.08&#8211;7.07), and the high infiltration of intratumoral TCD3<sup>+</sup> cells increased the risk of death related to the neoplasm by three times (<italic toggle="yes">p</italic> = 0.02, CI:1.19&#8211;7.8). Female dogs with metastases to regional lymph nodes also had a risk of death 6.5 (CI: 2.61&#8211;16.4) times higher. In the multivariate analysis, the only variable that remained associated with the risk of death was the presence of metastasis in lymph nodes, which was responsible for a three-fold increase in the risk of death from the disease (<italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="animals-15-00287-t005" ref-type="table">Table 5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-animals-15-00287"><title>4. Discussion</title><p>In canine neoplasms with a solid arrangement, the characteristics of tumor-infiltrating inflammatory cells were associated with survival time, univariate analysis, and some prognostic factors. The increase in the inflammatory infiltrate of lymphocytes and their subtypes was associated with some poor prognostic factors, such as higher mitotic count, Ki-67 expression, and a higher frequency of metastasis to lymph nodes.</p><p>Female dogs presenting neoplasms with a solid arrangement with a high density of intratumoral TILs and TCD3<sup>+</sup> cells had significantly lower specific survival time when compared to female dogs presenting neoplasms with a low density of intratumoral TILs and CD3<sup>+</sup> cells. This is in agreement with what is reported in women who also have luminal neoplasms, leading to an association of a high number of TILs with shorter survival time [<xref rid="B13-animals-15-00287" ref-type="bibr">13</xref>]. This is believed to be related to the type of lymphocytes present since mammary neoplasms with luminal immunophenotype have a lower percentage of TCD8<sup>+</sup> cells when compared to TN neoplasms [<xref rid="B11-animals-15-00287" ref-type="bibr">11</xref>]. TCD8<sup>+</sup> cells are involved with the anti-tumor response mechanism, leading to neoplastic cell lysis. In contrast, other types of T cells that favor cancer progression and shorten survival may be present, such as regulatory T cells (such as Foxp3) and CD4 helper 2 cells [<xref rid="B38-animals-15-00287" ref-type="bibr">38</xref>,<xref rid="B39-animals-15-00287" ref-type="bibr">39</xref>]. A limitation of this study was not identifying T lymphocyte subtypes, such as CD4<sup>+</sup> and CD8<sup>+</sup>, or Foxp3. However, we suggest the presence of a predominant immunosuppression and tolerance response in the tumor microenvironment.</p><p>The neoplasms with a solid arrangement evaluated were MME (9.8%), SPC (13.1%), CSP (14.8%), BC (31.1%), and MAME (31.1%). We had few neoplasms diagnosed as MME and SPC, which may be a limitation regarding the representativeness of the various histological types of these neoplasms. However, some of them are infrequent, as seen in a study reclassifying 72 cases of solid carcinomas in female dogs, where MME represented only 15% of these neoplasms [<xref rid="B40-animals-15-00287" ref-type="bibr">40</xref>].</p><p>There was a significant statistical predominance of lymphocytes in relation to neutrophils in all samples, corroborating other studies that evaluated the inflammatory infiltrate in several histological types of mammary neoplasms in female dogs [<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>,<xref rid="B25-animals-15-00287" ref-type="bibr">25</xref>]. Lymphocytes are the most studied cells in the tumor microenvironment of several canine neoplasms, such as oral and cutaneous melanomas [<xref rid="B41-animals-15-00287" ref-type="bibr">41</xref>,<xref rid="B42-animals-15-00287" ref-type="bibr">42</xref>], urothelial bladder cell carcinoma [<xref rid="B43-animals-15-00287" ref-type="bibr">43</xref>], and mammary cancer [<xref rid="B15-animals-15-00287" ref-type="bibr">15</xref>,<xref rid="B16-animals-15-00287" ref-type="bibr">16</xref>,<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>]. However, few authors specify the areas where this inflammation is located [<xref rid="B17-animals-15-00287" ref-type="bibr">17</xref>,<xref rid="B33-animals-15-00287" ref-type="bibr">33</xref>,<xref rid="B44-animals-15-00287" ref-type="bibr">44</xref>].</p><p>In canine mammary neoplasms with a solid arrangement, the stroma is often scarce among neoplastic nests, making it difficult to assess stromal lymphocytic inflammation as it is studied in women. Therefore, we evaluated peritumoral and intratumoral inflammation, as was already performed in other studies in veterinary medicine [<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>,<xref rid="B33-animals-15-00287" ref-type="bibr">33</xref>]. In women&#8217;s breast cancer, the evaluation of TILs focusses on the stromal area between neoplastic nests, and the percentage of the area occupied by the inflammation is used in prognostic and predictive analysis [<xref rid="B45-animals-15-00287" ref-type="bibr">45</xref>].</p><p>In histology, we identified that most of the evaluated neoplasms show a greater amount of infiltration of TILs in the peritumoral area (72.1%) in relation to the intratumoral area (<italic toggle="yes">p</italic> = 0.0001). In the evaluation of lymphocyte subtypes, the majority of neoplasms (93.4%) showed a significantly higher amount of T lymphocytes than B lymphocytes (<italic toggle="yes">p</italic> = 0.0001), similar to what has already been described in women [<xref rid="B46-animals-15-00287" ref-type="bibr">46</xref>], cats [<xref rid="B47-animals-15-00287" ref-type="bibr">47</xref>], and female dogs [<xref rid="B17-animals-15-00287" ref-type="bibr">17</xref>]. There was no statistical difference in the amount of TCD3 lymphocytes between the peri- and intratumoral areas in the samples, but CD79 B lymphocytes predominated in the peritumoral area (<italic toggle="yes">p</italic> = 0.02). Similar to what is seen in breast cancer in women, TCD3<sup>+</sup> cells show reasonable homogeneity in samples and may be around and inside the nests of tumor cells, while the CD20<sup>+</sup> cell, a marker used for B cells in women, is seen in less quantity and often forming peritumoral aggregates [<xref rid="B48-animals-15-00287" ref-type="bibr">48</xref>]. The formation of peritumoral lymphoid aggregates, which consist predominantly of B cells, is reported in in situ and invasive ductal carcinoma of women, indicating a host&#8217;s humoral immune response secondary to the neoplastic cell proliferation [<xref rid="B49-animals-15-00287" ref-type="bibr">49</xref>].</p><p>BCs are characterized by compact cell nest formations with cells presenting more hyperchromatic nuclei, especially in the periphery, where cells are organized into palisades [<xref rid="B30-animals-15-00287" ref-type="bibr">30</xref>]. This may cause greater difficulty in the visualization of lymphocytes within the tumor nests and may have influenced the lower intensity of intratumoral TILs we found in this histological type compared to the others (<italic toggle="yes">p</italic> = 0.02). Thus, we may infer that the histological and growth patterns of the neoplasm can interfere with the quantification of TILs, as described in women&#8217;s neoplasms [<xref rid="B45-animals-15-00287" ref-type="bibr">45</xref>].</p><p>As for immunophenotypes, only luminal A, luminal B HER-2 negative, and luminal B HER-2 positive immunophenotypes were diagnosed. In this study, neoplasms with luminal B HER-2 positive and negative immunophenotypes presented significantly higher density of intratumoral TCD3<sup>+</sup> lymphocyte infiltration when compared to those of luminal A immunophenotype (<italic toggle="yes">p</italic> = 0.04). The mammary cancer immunophenotype is known to influence the amount and composition of inflammatory infiltrate in the tumor microenvironment [<xref rid="B50-animals-15-00287" ref-type="bibr">50</xref>,<xref rid="B51-animals-15-00287" ref-type="bibr">51</xref>]. Canine luminal A neoplasms may present less activation of genes that produce proteins associated with immune mechanism and inflammatory stimulus than B immunophenotype neoplasms [<xref rid="B52-animals-15-00287" ref-type="bibr">52</xref>]. In women, luminal A mammary neoplasms have also been described as presenting a lower presence of TILs than luminal B HER-2 negative neoplasms [<xref rid="B53-animals-15-00287" ref-type="bibr">53</xref>]. Similarly, TN- and HER-2-overexpressed neoplasms also incite greater chemotaxis, both of lymphocytes [<xref rid="B14-animals-15-00287" ref-type="bibr">14</xref>,<xref rid="B15-animals-15-00287" ref-type="bibr">15</xref>,<xref rid="B39-animals-15-00287" ref-type="bibr">39</xref>] and neutrophils [<xref rid="B23-animals-15-00287" ref-type="bibr">23</xref>], due to greater genomic instability.</p><p>During the inflammatory process, several growth factors and cytokines that activate transcription factors are produced, such as NF-kB and STAT-3, which favor cell proliferation [<xref rid="B54-animals-15-00287" ref-type="bibr">54</xref>]. This is in agreement with what we observed, i.e., the high intensity of intra- and peritumoral lymphocyte inflammation was observed in neoplasms with a higher mitotic count and/or higher immunostaining of Ki-67. In the present study, a high mitotic count was associated with a high density of intratumoral TILs (<italic toggle="yes">p</italic> = 0.03) and CD79<sup>+</sup>cells (<italic toggle="yes">p</italic> = 0.02). In addition, both the mitotic count and Ki-67 immunostaining were proportionally related to the density of peritumoral CD3<sup>+</sup> and C79<sup>+</sup> cells. As cells proliferate, they can expose new antigens and induce a greater inflammatory response, primarily by cells of the innate immune system, such as TCD8 <sup>+</sup> and NK lymphocytes.</p><p>Metastasis to regional lymph nodes was significantly associated with a high density of intratumoral lymphocytes. This finding corroborates other studies of canine mammary tumors, describing a higher percentage of BCD79<sup>+</sup> cells infiltrating carcinoma in mixed tumors of animals presenting metastasis to lymph nodes [<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>] and greater peritumoral lymphatic invasion in several types of mammary carcinomas when compared to tumors with a low infiltration of such cells [<xref rid="B16-animals-15-00287" ref-type="bibr">16</xref>]. In canine melanoma, lymph node metastasis is also related to a moderate amount of intratumoral B cells in the primary neoplasm [<xref rid="B42-animals-15-00287" ref-type="bibr">42</xref>]. In both women and in experimental mouse models, an increased infiltration of B cells was detected in the microenvironment of neoplasms that metastasized to lymph nodes [<xref rid="B49-animals-15-00287" ref-type="bibr">49</xref>,<xref rid="B55-animals-15-00287" ref-type="bibr">55</xref>], and many of those lymphocytes were regulatory B cells, responsible for producing cytokines that reduce the anti-tumor function of T cells via the secretion of IL-10 [<xref rid="B49-animals-15-00287" ref-type="bibr">49</xref>,<xref rid="B56-animals-15-00287" ref-type="bibr">56</xref>]. In experimental models, such an increase in tumor B cells is associated with the appearance of stromal cells in the lymph node and an increase of transcription genes related to important signaling pathways in pre-metastatic nests in lymph nodes [<xref rid="B55-animals-15-00287" ref-type="bibr">55</xref>]. Even though CD79<sup>+</sup> B lymphocytes were associated with lymph node metastasis in the female dogs of the present study, the high infiltration of those did not influence the overall and specific survival time. However, we observed that the presence of lymph node metastasis increased the risk of death due to the neoplasm by six and three times in univariate and multivariate analysis, respectively, which makes it an independent prognostic factor. Metastasis to lymph nodes was also a factor that increased the risk of cancer-related death in female dogs in other studies [<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>,<xref rid="B35-animals-15-00287" ref-type="bibr">35</xref>].</p><p>Although we did not observe a significant association of neutrophils with the presence of metastasis to lymph nodes, 71,4% of the neoplasms that metastasized had a high density of peritumoral TANs (<italic toggle="yes">p</italic> = 0.05). In addition, intratumoral neutrophil infiltration generated an important difference in the overall survival time of female dogs; those with low intratumoral density had a median survival time of 425 days, while those with a high density of neutrophil infiltrate had a median survival time of 210 days (<italic toggle="yes">p</italic> = 0.04). In human medicine, few breast cancer articles make this association. One of them describes shorter survival time in patients with a high density of neutrophil infiltrate but without specifying the location [<xref rid="B24-animals-15-00287" ref-type="bibr">24</xref>]. To date, no other study associating tumor neutrophil infiltration with the survival of female dogs with mammary neoplasms is known.</p><p>Some studies associate a larger tumor size with a greater presence of TILs in women&#8217;s luminal neoplasms [<xref rid="B50-animals-15-00287" ref-type="bibr">50</xref>,<xref rid="B57-animals-15-00287" ref-type="bibr">57</xref>], but we did not observe a significant association of this variable with TILs, T cells (CD3<sup>+</sup>), B cells (CD79<sup>+</sup>), and neutrophils.</p><p>A higher Cox-2 score was associated with higher tumor inflammatory infiltrate in mammary neoplasms [<xref rid="B58-animals-15-00287" ref-type="bibr">58</xref>] and canine melanoma [<xref rid="B41-animals-15-00287" ref-type="bibr">41</xref>]. However, that finding was not observed in the present study. This may have occurred because we had only 28.8% of neoplasms marked for Cox-2, and most of them presented low scores. Cyclooxygenase is probably not an important factor for inflammatory stimulation in neoplasms with a solid arrangement; however, further studies should be conducted to confirm this hypothesis.</p><p>The blood neutrophil/lymphocyte ratio has been performed in patients with mammary carcinomas and is indicated as a prognostic factor in studies of cats [<xref rid="B59-animals-15-00287" ref-type="bibr">59</xref>]. In female dogs, a blood ratio &gt;5 N/L before surgery is associated with worse prognosis [<xref rid="B60-animals-15-00287" ref-type="bibr">60</xref>]. Here, we used the cell count in the tumor microenvironment to associate the ratio of N/L and CD79<sup>+</sup>/CD3<sup>+</sup> with survival, but it was not significant.</p><p>In a study of mammary neoplasms in female dogs, the animals presenting neoplasms with greater lymphocyte infiltration (&gt;600 lymphocytes/8 fields) had lower survival time, which was confirmed by the multivariate Cox regression analysis [<xref rid="B18-animals-15-00287" ref-type="bibr">18</xref>]. In the univariate analysis, we observed that the high density of intratumoral TILs and intratumoral T lymphocytes increased the risk of death from the neoplasm by 2.7 and 3 times, respectively, but this was not confirmed by the multivariate analysis.</p><p>We believe that by identifying the type of inflammatory cells present in these canine mammary tumors and understanding their influence on neoplastic progression, new therapeutic measures targeting immune system modulation can be researched and implemented. Furthermore, it will be possible to correlate the density and location of TILs with the response to chemotherapy, as described in women, where a higher quantity of TILs has been associated with a better response to chemotherapy [<xref rid="B13-animals-15-00287" ref-type="bibr">13</xref>,<xref rid="B14-animals-15-00287" ref-type="bibr">14</xref>,<xref rid="B39-animals-15-00287" ref-type="bibr">39</xref>].</p></sec><sec sec-type="conclusions" id="sec5-animals-15-00287"><title>5. Conclusions</title><p>In our study, we observed that neoplasms with a solid arrangement show a greater predominance of lymphocytes than neutrophils and mainly TCD3<sup>+</sup> cells. TCD3<sup>+</sup> cells predominated in the intratumoral area, while BCD79<sup>+</sup> cells predominated in the peritumoral area.</p><p>The infiltration of lymphocytes and their location in canine mammary neoplasms, evaluated here, are associated with some prognostic factors in female dogs. Nodal metastasis was associated with a high infiltration of intratumoral CD79<sup>+</sup> cells, and shorter survival time was associated with a high density of TILs and intratumoral T CD3<sup>+</sup> cells. Thus, lymphocyte infiltration, especially the intratumoral infiltration, may be an important feature in cancer progression, inciting a pro-tumor and regulatory response of the anti-tumor response and influencing the survival of female dogs with mammary neoplasms with a solid arrangement. However, in this study, it was not an independent prognostic factor.</p><p>We know that in the laboratory routine, the quantitative evaluation of inflammatory cells in the tumor microenvironment is difficult to carry out. However, the analysis of the intensity of peri- and intratumoral inflammation from a cutoff point can be performed in hematoxylin and eosin stains and associated with morphological characteristics to gather possible prognostic information.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the tutors and veterinarians for providing the necessary information to carry out this study and universities that provided slides and paraffin blocks to carry out the research.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-animals-15-00287"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ani15020287/s1">https://www.mdpi.com/article/10.3390/ani15020287/s1</uri>, Figure S1. Canine Mammary Neoplasms with Solid Arrangement. Malignant Adenomyoepithelioma: A. Neoplastic cells were organized in mantles or solid nests, with scarce tubules and stroma, HE, bar = 100 &#181;m. B. Immunolabelling for pancytokeratin in the cytoplasm of epithelial cells, bar = 50 &#181;m. C. Immunolabelling for p63 in the nuclei of myoepithelial cells, bar = 50 &#181;m. Carcinomas with Solid Pattern: D. Neoplastic cells were organized in solid nests, HE, bar = 100 &#181;m. E. Immunolabelling for pancytokeratin in the cytoplasm of epithelial cells, bar = 50 &#181;m. F. No immunostaining for p63, bar = 50 &#181;m. Basaloid carcinoma: G. solid nests surrounded by a layer of peripheral palisading cells (arrow head), multinodular pattern separated by moderate fibrous stroma (*), HE, bar = 100 &#181;m. H. Central cells immunolabelled for pancytokeratin, bar = 50 &#181;m. I. Palisading peripheral cells stained with cytokeratin 14 (arrow), bar = 50 &#181;m. Malignant Myoepithelioma: J. Elongated and rounded cells oriented in various directions, HE, bar = 100 &#181;m. K. Cells with clear cytoplasm, round nuclei, and intercellular myxoid material (*), HE, bar = 50 &#181;m. L. Immunolabelling for p63 in the nuclei of myoepithelial cells, bar = 50 &#181;m. Solid Papillary Carcinomas: M. Papillary projections with multiple layers of epithelial cells extending from the stroma (arrow), forming a solid appearance, HE, bar = 100 &#181;m. N. Delicate fibrous stroma (arrow) supporting the layers of epithelial cells, Gomori&#8217;s trichrome, bar = 50 &#181;m. O. Immunolabelling for pancytokeratin in the cytoplasm of epithelial cells, bar = 50 &#181;m. Figure S2. Immunohistochemistry for estrogen receptor in Canine Mammary Neoplasms with Solid Arrangement. A. Negative immunostaining (&lt;1%). B. Nuclear staining in a few cells (1&#8211;25% of labeled cells) (arrow). C. 26&#8211;50% of labeled cells. D. 51&#8211;75% of labeled cells. E. More than 75% of labeled cells. F. Positive control in the mammary gland of a non-neoplastic female dog. Bar = 50 um. Figure S3. Immunohistochemistry for progesterone receptor in Canine Mammary Neoplasms with Solid Arrangement. A. Negative immunostaining (&lt;1%). B. Nuclear staining in a few cells (1&#8211;25% of labeled cells) (arrow). C. 26&#8211;50% of labeled cells. D. 51&#8211;75% of labeled cells. E. More than 75% of labeled cells. F. Positive control in the mammary gland of a non-neoplastic female dog. Bar = 50 um. Figure S4. Immunohistochemistry for Ki-67 in Canine Mammary Neoplasms with Solid Arrangement. A. Neoplasm with a high nuclear staining count for Ki-67, showing &gt;20% of cells with nuclear staining. B. Neoplasm with a low nuclear staining count for Ki-67, showing &lt;20% of cells with nuclear staining. Bar = 50 um. Figure S5. Immunohistochemistry for HER-2 in Canine Mammary Neoplasms with Solid Arrangement followed the guidelines of membrane marking score (Wolff et al., 2013) [<xref rid="B36-animals-15-00287" ref-type="bibr">36</xref>]. A. Neoplasm with score 1. B. Neoplasm with score 2. C. Neoplasm with score 3. Bar = 50 um. Figure S6. Immunohistochemistry for COX-2 in Canine Mammary Neoplasms with Solid Arrangement, based on a semi-quantitative evaluation of labeled tumor cells in the cytoplasm (Lavalle et al., 2009) [<xref rid="B37-animals-15-00287" ref-type="bibr">37</xref>]. A. Neoplasm without immunostaining for COX-2. B. Neoplasm with a score of 1 (less than 10% of cells labeled; weak intensity) (arrow). C. Neoplasm with a score of 3 (less than 10% of cells labeled; strong intensity) (arrow). Bar = 50 &#181;m.</p><supplementary-material id="animals-15-00287-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="animals-15-00287-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>M.C.F.&#8212;Conceptualization, Methodology, Investigation, Writing&#8212;Review and Editing, Writing&#8212;Original Draft, Visualization. M.P.R.&#8212;Investigation, Writing. D.B.&#8212;Formal analysis, Writing&#8212;Review and Editing; K.Y.R.N.&#8212;Conceptualization, Methodology; G.D.C.&#8212;Conceptualization, Methodology, Investigation, Writing&#8212;Review and Editing, Writing&#8212;Original Draft, Funding acquisition, Project administration. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the ethical principles for the use of animals in experimentation approved by CEUA&#8211;UFMG (No.11/2017).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are contained within the article and <xref rid="app1-animals-15-00287" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-animals-15-00287"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klintrup</surname><given-names>K.</given-names></name><name name-style="western"><surname>M&#228;kinen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kauppila</surname><given-names>S.</given-names></name><name name-style="western"><surname>V&#228;re</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Melkko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tuominen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tuppurainen</surname><given-names>K.</given-names></name><name name-style="western"><surname>M&#228;kel&#228;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karttunen</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>M&#228;kinen</surname><given-names>M.J.</given-names></name></person-group><article-title>Inflammation and prognosis in colorectal cancer</article-title><source>Eur. J. Cancer</source><year>2005</year><volume>41</volume><fpage>2645</fpage><lpage>2654</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2005.07.017</pub-id><pub-id pub-id-type="pmid">16239109</pub-id></element-citation></ref><ref id="B2-animals-15-00287"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mlecnik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tosolini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kirilovsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bindea</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meatchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bruneval</surname><given-names>P.</given-names></name><name name-style="western"><surname>Trajanoski</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fridman</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Pag&#232;s</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction</article-title><source>J. Clin. Oncol.</source><year>2011</year><volume>29</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.30.5425</pub-id><pub-id pub-id-type="pmid">21245428</pub-id></element-citation></ref><ref id="B3-animals-15-00287"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galdiero</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grizzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Caro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Basso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ponzetta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonavita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barbagallo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tartari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Polentarutti</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer</article-title><source>Int. J. Cancer</source><year>2016</year><volume>139</volume><fpage>446</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1002/ijc.30076</pub-id><pub-id pub-id-type="pmid">26939802</pub-id></element-citation></ref><ref id="B4-animals-15-00287"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hiratsuka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koike</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsuchihashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sonoda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ogi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyakawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Igarashi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Tumor-infiltrating CD8<sup>+</sup> T-cell density is an independent prognostic marker for oral squamous cell carcinoma</article-title><source>Cancer Med.</source><year>2019</year><volume>8</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/cam4.1889</pub-id><pub-id pub-id-type="pmid">30600646</pub-id><pub-id pub-id-type="pmcid">PMC6346233</pub-id></element-citation></ref><ref id="B5-animals-15-00287"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stravodimou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tzelepi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Papadaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mouzaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Georgiou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Melachrinou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kourea</surname><given-names>E.P.</given-names></name></person-group><article-title>T-lymphocytes and their subpopulations in invasive and in situ squamous cell carcinoma of the skin and actinic keratosis</article-title><source>J. Cutan. Pathol.</source><year>2018</year><volume>45</volume><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1111/cup.13123</pub-id><pub-id pub-id-type="pmid">29419888</pub-id></element-citation></ref><ref id="B6-animals-15-00287"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Donskov</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name></person-group><article-title>Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e98259</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0098259</pub-id><pub-id pub-id-type="pmid">24906014</pub-id><pub-id pub-id-type="pmcid">PMC4048155</pub-id></element-citation></ref><ref id="B7-animals-15-00287"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>H.</given-names></name></person-group><article-title>Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients</article-title><source>Tumor Biol.</source><year>2015</year><volume>36</volume><fpage>7907</fpage><lpage>7913</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3507-y</pub-id><pub-id pub-id-type="pmid">25953262</pub-id></element-citation></ref><ref id="B8-animals-15-00287"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name></person-group><article-title>Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis</article-title><source>Clin. Transl. Oncol.</source><year>2015</year><volume>18</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1007/s12094-015-1391-y</pub-id><pub-id pub-id-type="pmid">26459255</pub-id><pub-id pub-id-type="pmcid">PMC4823351</pub-id></element-citation></ref><ref id="B9-animals-15-00287"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>E.</given-names></name></person-group><article-title>The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer</article-title><source>Pathol.-Res. Pract.</source><year>2018</year><volume>214</volume><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2018.05.010</pub-id><pub-id pub-id-type="pmid">29803657</pub-id></element-citation></ref><ref id="B10-animals-15-00287"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denkert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Loibl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Noske</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roller</surname><given-names>M.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Komor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Budczies</surname><given-names>J.</given-names></name><name name-style="western"><surname>Darb-Esfahani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kronenwett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hanusch</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.7370</pub-id><pub-id pub-id-type="pmid">19917869</pub-id></element-citation></ref><ref id="B11-animals-15-00287"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoud</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Paish</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Powe</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Macmillan</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Grainge</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>I.O.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.R.</given-names></name></person-group><article-title>Tumor-Infiltrating CD8<sup>+</sup> Lymphocytes Predict Clinical Outcome in Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2011</year><volume>29</volume><fpage>1949</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.30.5037</pub-id><pub-id pub-id-type="pmid">21483002</pub-id></element-citation></ref><ref id="B12-animals-15-00287"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>A Mohammed</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Going</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elsberger</surname><given-names>B.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>D.C.</given-names></name></person-group><article-title>The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer</article-title><source>Br. J. Cancer</source><year>2013</year><volume>109</volume><fpage>1676</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.493</pub-id><pub-id pub-id-type="pmid">23982600</pub-id><pub-id pub-id-type="pmcid">PMC3777002</pub-id></element-citation></ref><ref id="B13-animals-15-00287"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.-X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: A meta-analysis</article-title><source>BMC Cancer</source><year>2020</year><volume>20</volume><fpage>1150</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1186/s12885-020-07654-y</pub-id><pub-id pub-id-type="pmid">33238978</pub-id><pub-id pub-id-type="pmcid">PMC7690150</pub-id></element-citation></ref><ref id="B14-animals-15-00287"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>G.</given-names></name></person-group><article-title>Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab</article-title><source>Am. J. Clin. Pathol.</source><year>2015</year><volume>144</volume><fpage>278</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1309/AJCPIXUYDVZ0RZ3G</pub-id><pub-id pub-id-type="pmid">26185313</pub-id></element-citation></ref><ref id="B15-animals-15-00287"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>D.</given-names></name></person-group><article-title>Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>44288</fpage><lpage>44298</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9988</pub-id><pub-id pub-id-type="pmid">27329588</pub-id><pub-id pub-id-type="pmcid">PMC5190096</pub-id></element-citation></ref><ref id="B16-animals-15-00287"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Chon</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Im</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.-H.</given-names></name><name name-style="western"><surname>Sur</surname><given-names>J.-H.</given-names></name></person-group><article-title>Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study</article-title><source>Can. J. Vet. Res.</source><year>2013</year><volume>77</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">24082407</pub-id><pub-id pub-id-type="pmcid">PMC3605931</pub-id></element-citation></ref><ref id="B17-animals-15-00287"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muscatello</surname><given-names>L.</given-names></name><name name-style="western"><surname>Avallone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bacci</surname><given-names>B.</given-names></name><name name-style="western"><surname>Foschini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarli</surname><given-names>G.</given-names></name></person-group><article-title>Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: Spatial distribution and score as relevant features of tumor malignancy</article-title><source>Vet. J.</source><year>2022</year><volume>283&#8211;284</volume><fpage>105833</fpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2022.105833</pub-id><pub-id pub-id-type="pmid">35489672</pub-id></element-citation></ref><ref id="B18-animals-15-00287"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estrela-Lima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Costa-Neto</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Teixeira-Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrouin-Melo</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>A Martins-Filho</surname><given-names>O.</given-names></name><name name-style="western"><surname>Serakides</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cassali</surname><given-names>G.D.</given-names></name></person-group><article-title>Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><fpage>256</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1186/1471-2407-10-256</pub-id><pub-id pub-id-type="pmid">20525350</pub-id><pub-id pub-id-type="pmcid">PMC2894795</pub-id></element-citation></ref><ref id="B19-animals-15-00287"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abadie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loussouarn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>N.</given-names></name><name name-style="western"><surname>Belousov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bemelmans</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jaillardon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ibisch</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Canine invasive mammary carcinomas as models of human breast cancer. Part 2: Immunophenotypes and prognostic significance</article-title><source>Breast Cancer Res. Treat.</source><year>2017</year><volume>167</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1007/s10549-017-4542-8</pub-id><pub-id pub-id-type="pmid">29063312</pub-id><pub-id pub-id-type="pmcid">PMC5790838</pub-id></element-citation></ref><ref id="B20-animals-15-00287"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Queen</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Holzer</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Keller-Peck</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Jorcyk</surname><given-names>C.L.</given-names></name></person-group><article-title>Breast Cancer Cells Stimulate Neutrophils to Produce Oncostatin M: Potential Implications for Tumor Progression</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>8896</fpage><lpage>8904</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1734</pub-id><pub-id pub-id-type="pmid">16204061</pub-id></element-citation></ref><ref id="B21-animals-15-00287"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timaxian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>C.F.A.</given-names></name><name name-style="western"><surname>Orcel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vetter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Durochat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chinal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aknin</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Mercier-Nom&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Davy</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>2584</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13112584</pub-id><pub-id pub-id-type="pmid">34070438</pub-id><pub-id pub-id-type="pmcid">PMC8197482</pub-id></element-citation></ref><ref id="B22-animals-15-00287"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Abrahamsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>L.D.E.</given-names></name><name name-style="western"><surname>Dabrosin</surname><given-names>C.</given-names></name></person-group><article-title>Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils</article-title><source>Cancer Immunol. Res.</source><year>2017</year><volume>5</volume><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0150</pub-id><pub-id pub-id-type="pmid">28159748</pub-id></element-citation></ref><ref id="B23-animals-15-00287"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soto-Perez-De-Celis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chavarri-Guerra</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leon-Rodriguez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gamboa-Dominguez</surname><given-names>A.</given-names></name></person-group><article-title>Tumor-Associated Neutrophils in Breast Cancer Subtypes</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2017</year><volume>18</volume><fpage>2689</fpage><lpage>2693</lpage><pub-id pub-id-type="doi">10.22034/APJCP.2017.18.10.2689</pub-id><pub-id pub-id-type="pmid">29072393</pub-id><pub-id pub-id-type="pmcid">PMC5747391</pub-id></element-citation></ref><ref id="B24-animals-15-00287"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwantwi</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name></person-group><article-title>Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer</article-title><source>Bioengineered</source><year>2021</year><volume>12</volume><fpage>6996</fpage><lpage>7006</lpage><pub-id pub-id-type="doi">10.1080/21655979.2021.1977102</pub-id><pub-id pub-id-type="pmid">34519637</pub-id><pub-id pub-id-type="pmcid">PMC8806641</pub-id></element-citation></ref><ref id="B25-animals-15-00287"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>de Campos</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>De Biasi Bassani Goncalves</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>de Oliveira Vasconcelos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cassali</surname><given-names>G.D.</given-names></name></person-group><article-title>Relationship between the inflammatory tumor microenvironment and different histologic types of canine mammary tumors</article-title><source>Res. Vet. Sci.</source><year>2018</year><volume>119</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2018.06.012</pub-id><pub-id pub-id-type="pmid">29966962</pub-id></element-citation></ref><ref id="B26-animals-15-00287"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flecher</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Balabram</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salles</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Estrela-Lima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name><name name-style="western"><surname>Cassali</surname><given-names>G.D.</given-names></name></person-group><article-title>Evaluation of im-munophenotype and inflammation in canine mammary neoplasms with solid arrangement</article-title><source>J. Comp. Pathol.</source><year>2024</year><volume>16</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2024.06.004</pub-id><pub-id pub-id-type="pmid">39018987</pub-id></element-citation></ref><ref id="B27-animals-15-00287"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zappulli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pena</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rasotto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goldschmidt</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Gama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scruggs</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kiupel</surname><given-names>M.</given-names></name></person-group><article-title>Volume 2: Mammary Tumors</article-title><source>Surgical Pathology of Tumors of Domestic Animals Kiupel, M., Ed.</source><publisher-name>Davis-Thompson DVM Foundation</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2019</year><fpage>1</fpage><lpage>195</lpage></element-citation></ref><ref id="B28-animals-15-00287"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jark</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gamba</surname><given-names>C.</given-names></name><name name-style="western"><surname>Damasceno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Estrela-Lima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Horta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Firmo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sueiro</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Consensus Regarding the Diagnosis, Prognosis and Treatment of Canine and Feline Mammary Tumors&#8212;2019</article-title><source>Braz. J. Vet. Pathol.</source><year>2020</year><volume>13</volume><fpage>555</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.24070/bjvp.1983-0246.v13i3p555-574</pub-id></element-citation></ref><ref id="B29-animals-15-00287"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasotto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berlato</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goldschmidt</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Zappulli</surname><given-names>V.</given-names></name></person-group><article-title>Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases</article-title><source>Vet. Pathol.</source><year>2017</year><volume>54</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1177/0300985817698208</pub-id><pub-id pub-id-type="pmid">28355108</pub-id></element-citation></ref><ref id="B30-animals-15-00287"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagaki</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>A.P.V.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cassali</surname><given-names>G.D.</given-names></name></person-group><article-title>Solid Carcinoma of the Canine Mammary Gland: A Histological Type or Tumour Cell Arrangement?</article-title><source>J. Comp. Pathol.</source><year>2022</year><volume>190</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2021.10.011</pub-id><pub-id pub-id-type="pmid">35152966</pub-id></element-citation></ref><ref id="B31-animals-15-00287"><label>31.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Elston </surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>I.O.</given-names></name></person-group><article-title>Assessment of histological grade</article-title><source>Systemic Pathology</source><person-group person-group-type="editor"><name name-style="western"><surname>Elston</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>I.O.</given-names></name></person-group><publisher-name>The Breast</publisher-name><publisher-loc>London, UK</publisher-loc><year>1998</year><fpage>365</fpage><lpage>384</lpage></element-citation></ref><ref id="B32-animals-15-00287"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>L.N.</given-names></name></person-group><source>TNM Classification of Tumours in Domestic Animals</source><edition>1st ed.</edition><publisher-name>Word Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>1980</year></element-citation></ref><ref id="B33-animals-15-00287"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vieira</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>dos Santos</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Veloso</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Del Puerto</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Cassali</surname><given-names>G.D.</given-names></name></person-group><article-title>COX-2 expression in mammary invasive micropapillary carcinoma is associated with prognostic factors and acts as a potential therapeutic target in comparative oncology</article-title><source>Front. Veter.-Sci.</source><year>2022</year><volume>9</volume><elocation-id>983110</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2022.983110</pub-id><pub-id pub-id-type="pmcid">PMC9510711</pub-id><pub-id pub-id-type="pmid">36172611</pub-id></element-citation></ref><ref id="B34-animals-15-00287"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammond</surname><given-names>M.E.H.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Dowsett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allred</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Hagerty</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Badve</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fitzgibbons</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>M.</given-names></name><etal/></person-group><article-title>American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>2784</fpage><lpage>2795</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.6529</pub-id><pub-id pub-id-type="pmid">20404251</pub-id><pub-id pub-id-type="pmcid">PMC2881855</pub-id></element-citation></ref><ref id="B35-animals-15-00287"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bertagnolli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lavalle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Balabram</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cassali</surname><given-names>G.</given-names></name></person-group><article-title>The prognostic significance of immunophenotypes in canine malignant mammary tumors</article-title><source>Arq. Bras. Med. Vet.-E Zootec.</source><year>2022</year><volume>74</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1590/1678-4162-12273</pub-id></element-citation></ref><ref id="B36-animals-15-00287"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>M.E.H.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Dowsett</surname><given-names>M.</given-names></name><name name-style="western"><surname>McShane</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Allred</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J.M.S.</given-names></name><name name-style="western"><surname>Bilous</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fitzgibbons</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>3997</fpage><lpage>4013</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.9984</pub-id><pub-id pub-id-type="pmid">24101045</pub-id></element-citation></ref><ref id="B37-animals-15-00287"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavalle</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Bertagnolli</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>W.L.F.</given-names></name><name name-style="western"><surname>Cassali</surname><given-names>G.D.</given-names></name></person-group><article-title>Cox-2 Expression in Canine Mammary Carcinomas</article-title><source>Vet. Pathol.</source><year>2009</year><volume>46</volume><fpage>1275</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1354/vp.08-VP-0226-C-FL</pub-id><pub-id pub-id-type="pmid">19605908</pub-id></element-citation></ref><ref id="B38-animals-15-00287"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hunborg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varvares</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hoft</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>E.C.</given-names></name><etal/></person-group><article-title>CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>17462</fpage><lpage>17478</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3958</pub-id><pub-id pub-id-type="pmid">25968569</pub-id><pub-id pub-id-type="pmcid">PMC4627321</pub-id></element-citation></ref><ref id="B39-animals-15-00287"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koletsa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kotoula</surname><given-names>V.</given-names></name><name name-style="western"><surname>Koliou</surname><given-names>G.-A.</given-names></name><name name-style="western"><surname>Manousou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chrisafi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zagouri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sotiropoulou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pentheroudakis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Papoudou-Bai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Christodoulou</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: Do they add information over stromal tumor-infiltrating lymphocyte density?</article-title><source>Cancer Immunol. Immunother.</source><year>2020</year><volume>69</volume><fpage>1549</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02557-0</pub-id><pub-id pub-id-type="pmid">32303794</pub-id><pub-id pub-id-type="pmcid">PMC11027646</pub-id></element-citation></ref><ref id="B40-animals-15-00287"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakahira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Michishita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohkusu-Tsukada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name></person-group><article-title>Differences in Indicators of Malignancy Between Luminal Epithelial Cell Type and Myoepithelial Cell Type of Simple Solid Carcinoma in the Canine Mammary Gland</article-title><source>Vet. Pathol.</source><year>2014</year><volume>51</volume><fpage>1090</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1177/0300985813516637</pub-id><pub-id pub-id-type="pmid">24448671</pub-id></element-citation></ref><ref id="B41-animals-15-00287"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greg&#243;rio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raposo</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Queiroga</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Prada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>I.</given-names></name></person-group><article-title>Investigating associations of cyclooxygenase-2 expression with angiogenesis, proliferation, macrophage and T-lymphocyte infiltration in canine melanocytic tumours</article-title><source>Melanoma Res.</source><year>2016</year><volume>26</volume><fpage>338</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000262</pub-id><pub-id pub-id-type="pmid">27105172</pub-id></element-citation></ref><ref id="B42-animals-15-00287"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porcellato</surname><given-names>I.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Menchetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Recupero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mechelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sforna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iussich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bongiovanni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lepri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brachelente</surname><given-names>C.</given-names></name></person-group><article-title>Tumour-infiltrating lymphocytes in canine melanocytic tumours: An investigation on the prognostic role of CD3<sup>+</sup> and CD20<sup>+</sup> lymphocytic populations</article-title><source>Vet. Comp. Oncol.</source><year>2019</year><volume>18</volume><fpage>370</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1111/vco.12556</pub-id><pub-id pub-id-type="pmid">31750993</pub-id></element-citation></ref><ref id="B43-animals-15-00287"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yonezawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuki</surname><given-names>N.</given-names></name></person-group><article-title>Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma</article-title><source>Vet. Immunol. Immunopathol.</source><year>2017</year><volume>190</volume><fpage>53</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2017.07.001</pub-id><pub-id pub-id-type="pmid">28778323</pub-id></element-citation></ref><ref id="B44-animals-15-00287"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Queiroga</surname><given-names>F.L.</given-names></name></person-group><article-title>T-lymphocytic infiltrate in canine mammary tumours: Clinic and prognostic implications</article-title><source>In Vivo.</source><year>2011</year><volume>25</volume><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">22021690</pub-id></element-citation></ref><ref id="B45-animals-15-00287"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salgado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Denkert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Demaria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sirtaine</surname><given-names>N.</given-names></name><name name-style="western"><surname>Klauschen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pruneri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wienert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van den Eynden</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baehner</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Penault-Llorca</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014</article-title><source>Ann. Oncol.</source><year>2015</year><volume>26</volume><fpage>259</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu450</pub-id><pub-id pub-id-type="pmid">25214542</pub-id><pub-id pub-id-type="pmcid">PMC6267863</pub-id></element-citation></ref><ref id="B46-animals-15-00287"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-&#924;acias</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Molinar-Flores</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lopez-Garcia</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Santuario-Facio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Decanini-Arcaute</surname><given-names>H.</given-names></name><name name-style="western"><surname>Valero-Elizondo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Trevi&#241;o-Alvarado</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ortiz-Lopez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dono</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esteban-Zubero</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization</article-title><source>Oncol. Lett.</source><year>2020</year><volume>20</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.3892/ol.2020.12000</pub-id><pub-id pub-id-type="pmid">32934708</pub-id><pub-id pub-id-type="pmcid">PMC7471657</pub-id></element-citation></ref><ref id="B47-animals-15-00287"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nascimento</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gameiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>F.</given-names></name></person-group><article-title>The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>2578</elocation-id><pub-id pub-id-type="doi">10.3390/cells11162578</pub-id><pub-id pub-id-type="pmid">36010653</pub-id><pub-id pub-id-type="pmcid">PMC9406662</pub-id></element-citation></ref><ref id="B48-animals-15-00287"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mani</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Schalper</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hatzis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saglam</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tavassoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chagpar</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Pusztai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>D.L.</given-names></name></person-group><article-title>Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer</article-title><source>Breast Cancer Res.</source><year>2016</year><volume>18</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1186/s13058-016-0737-x</pub-id><pub-id pub-id-type="pmid">27473061</pub-id><pub-id pub-id-type="pmcid">PMC4966732</pub-id></element-citation></ref><ref id="B49-animals-15-00287"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishigami</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sakakibara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sakakibara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sangai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakatani</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer</article-title><source>Breast Cancer</source><year>2018</year><volume>26</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1007/s12282-018-0910-4</pub-id><pub-id pub-id-type="pmid">30244409</pub-id></element-citation></ref><ref id="B50-animals-15-00287"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glajcar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szpor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hodorowicz-Zaniewska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tyrak</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Oko&#324;</surname><given-names>K.</given-names></name></person-group><article-title>The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status</article-title><source>Virchows Arch.</source><year>2019</year><volume>475</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s00428-019-02568-y</pub-id><pub-id pub-id-type="pmid">31016433</pub-id><pub-id pub-id-type="pmcid">PMC6611750</pub-id></element-citation></ref><ref id="B51-animals-15-00287"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Abubakar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>K.H.</given-names></name><etal/></person-group><article-title>Immune gene expression profiling reveals heterogeneity in luminal breast tumors</article-title><source>Breast Cancer Res.</source><year>2019</year><volume>21</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1186/s13058-019-1218-9</pub-id><pub-id pub-id-type="pmid">31856876</pub-id><pub-id pub-id-type="pmcid">PMC6924001</pub-id></element-citation></ref><ref id="B52-animals-15-00287"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergholtz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lien</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lingaas</surname><given-names>F.</given-names></name><name name-style="western"><surname>S&#248;rlie</surname><given-names>T.</given-names></name></person-group><article-title>Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors</article-title><source>J. Mammary Gland. Biol. Neoplasia</source><year>2022</year><volume>27</volume><fpage>171</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1007/s10911-022-09523-9</pub-id><pub-id pub-id-type="pmid">35932380</pub-id><pub-id pub-id-type="pmcid">PMC9433360</pub-id></element-citation></ref><ref id="B53-animals-15-00287"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Criscitiello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vingiani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maisonneuve</surname><given-names>P.</given-names></name><name name-style="western"><surname>Viale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Curigliano</surname><given-names>G.</given-names></name></person-group><article-title>Tumor-infiltrating lymphocytes (TILs) in ER+/HER2&#8722; breast cancer</article-title><source>Breast Cancer Res. Treat.</source><year>2020</year><volume>183</volume><fpage>347</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1007/s10549-020-05771-7</pub-id><pub-id pub-id-type="pmid">32621251</pub-id></element-citation></ref><ref id="B54-animals-15-00287"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrihari</surname><given-names>T.</given-names></name></person-group><article-title>Dual role of inflammatory mediators in cancer</article-title><source>Ecancer</source><year>2017</year><volume>11</volume><fpage>721</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.3332/ecancer.2017.721</pub-id><pub-id pub-id-type="pmid">28275390</pub-id><pub-id pub-id-type="pmcid">PMC5336391</pub-id></element-citation></ref><ref id="B55-animals-15-00287"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>312</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0309-y</pub-id><pub-id pub-id-type="pmid">30643287</pub-id></element-citation></ref><ref id="B56-animals-15-00287"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lundy</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10</article-title><source>Eur. J. Immunol.</source><year>2014</year><volume>45</volume><fpage>999</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1002/eji.201444625</pub-id><pub-id pub-id-type="pmid">25545618</pub-id><pub-id pub-id-type="pmcid">PMC4414939</pub-id></element-citation></ref><ref id="B57-animals-15-00287"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murazawa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kuraishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Motoyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S.-I.</given-names></name><name name-style="western"><surname>Ikeuchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Norimura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Teramoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Haba</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Status and prognostic value of immunological biomarkers of breast cancer</article-title><source>Oncol. Lett.</source><year>2023</year><volume>25</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.3892/ol.2023.13750</pub-id><pub-id pub-id-type="pmid">36960188</pub-id><pub-id pub-id-type="pmcid">PMC10028224</pub-id></element-citation></ref><ref id="B58-animals-15-00287"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raposo</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Greg&#243;rio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Queiroga</surname><given-names>F.L.</given-names></name></person-group><article-title>High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: A multivariate survival study</article-title><source>Vet. Comp. Oncol.</source><year>2016</year><volume>15</volume><fpage>619</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1111/vco.12206</pub-id><pub-id pub-id-type="pmid">26792550</pub-id></element-citation></ref><ref id="B59-animals-15-00287"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrucci</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Queiroga</surname><given-names>F.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>I.</given-names></name><name name-style="western"><surname>Henriques</surname><given-names>J.</given-names></name></person-group><article-title>Neutrophil-to-lymphocyte ratio is an independent prognostic marker for feline mammary carcinomas</article-title><source>Vet. Comp. Oncol.</source><year>2021</year><volume>19</volume><fpage>482</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1111/vco.12686</pub-id><pub-id pub-id-type="pmid">33576562</pub-id></element-citation></ref><ref id="B60-animals-15-00287"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uribe-Querol</surname><given-names>E.</given-names></name><name name-style="western"><surname>Romero-Romero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Govezensky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rosales</surname><given-names>C.</given-names></name></person-group><article-title>Neutrophil to lymphocyte ratio and principal component analysis offer prognostic advantage for dogs with mammary tumors</article-title><source>Front. Vet. Sci.</source><year>2023</year><volume>10</volume><elocation-id>1187271</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2023.1187271</pub-id><pub-id pub-id-type="pmid">37396996</pub-id><pub-id pub-id-type="pmcid">PMC10312309</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="animals-15-00287-f001" orientation="portrait"><label>Figure 1</label><caption><p>A comparison of the density of TILs in relation to the types of neoplasms with a solid arrangement of the canine mammary gland by Fisher&#8217;s exact test. (<bold>A</bold>) The density of the infiltration of peritumoral TILs between histological types. (<bold>B</bold>) The predominance of neoplasms with a high density of intratumoral TILs in MME, SPC, CSP, and MAME, except BC (<italic toggle="yes">p</italic> = 0.02). MME: Malignant myoepithelioma; SPC: solid papillary carcinoma; CSP: carcinoma with a solid pattern; BC: basaloid carcinoma; MAME: malignant adenomyoepithelioma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="animals-15-00287-g001.jpg"/></fig><fig position="float" id="animals-15-00287-f002" orientation="portrait"><label>Figure 2</label><caption><p>Density of inflammatory infiltrate in basaloid carcinoma compared to carcinoma with solid pattern. (<bold>A</bold>&#8211;<bold>D</bold>) TILs on slides stained with H&amp;E (600&#215;); (<bold>A</bold>) Low amount of peritumoral TIL in BC (arrow); (<bold>B</bold>) intratumoral TIL in BC; (<bold>C</bold>) high peritumoral TIL in CSP; (<bold>D</bold>) high intratumoral TIL and forming aggregates in CSP (white asterisk); (<bold>E</bold>&#8211;<bold>H</bold>) infiltrate of TCD3<sup>+</sup> cells in immunohistochemistry (400&#215;); (<bold>E</bold>) low amount of peritumoral lymphocytes in BC (arrow); (<bold>F</bold>) small aggregates of intratumoral lymphocytes in contact with neoplastic cells in BC (circle); (<bold>G</bold>) high infiltration of peritumoral lymphocytes in CSP; (<bold>H</bold>) high infiltration of intratumoral lymphocytes in CSP; (<bold>I</bold>&#8211;<bold>L</bold>) infiltrate of TCD79<sup>+</sup> cells in immunohistochemistry (400&#215;); (<bold>I</bold>) low infiltration of peritumoral lymphocytes in BC (arrow); (<bold>J</bold>) low infiltration of intratumoral lymphocytes in BC (circle); (<bold>K</bold>) high infiltration of peritumoral lymphocytes in CSP; (<bold>L</bold>) high infiltration of intratumoral lymphocytes in CSP (arrow).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="animals-15-00287-g002.jpg"/></fig><fig position="float" id="animals-15-00287-f003" orientation="portrait"><label>Figure 3</label><caption><p>Density of infiltration of TCD3<sup>+</sup> and BCD79<sup>+</sup> relative to luminal A, luminal B HER-2 negative, and luminal B HER-2 positive immunophenotypes in solid arrangement neoplasms, Fisher&#8217;s exact test. (<bold>A</bold>) Density of peritumoral (PT) TCD3<sup>+</sup>cells (<italic toggle="yes">p</italic> = 0.28); (<bold>B</bold>) luminal B neoplasms having higher density of intratumoral (IT) TCD3<sup>+</sup> cells compared to luminal A (<italic toggle="yes">p</italic> = 0.04 *); (<bold>C</bold>) density of peritumoral (PT) BCD79<sup>+</sup> cell infiltration (<italic toggle="yes">p</italic> = 0.92); (<bold>D</bold>) density of intratumoral (IT) BCD79<sup>+</sup> cells (<italic toggle="yes">p</italic> = 0.71). LA: luminal A; LB: luminal B.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="animals-15-00287-g003.jpg"/></fig><fig position="float" id="animals-15-00287-f004" orientation="portrait"><label>Figure 4</label><caption><p>The density of the inflammatory infiltrate in relation to the presence of metastases in regional lymph nodes. Fisher&#8217;s exact test. (<bold>A</bold>) The infiltration of peritumoral BCD79<sup>+</sup> cells showed no difference between neoplasms with or without lymph node metastases (<italic toggle="yes">p</italic> = 0.59). (<bold>B</bold>) The infiltration of intratumoral BCD79<sup>+</sup> cells was high in female dogs that had metastasis compared to those that did not (<italic toggle="yes">p</italic> = 0.02). * Statistically significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="animals-15-00287-g004.jpg"/></fig><fig position="float" id="animals-15-00287-f005" orientation="portrait"><label>Figure 5</label><caption><p>Association of peritumoral inflammation density with immunostaining for Ki-67 in neoplasms with solid arrangement. Mann&#8211;Whitney&#8217;s test. (<bold>A</bold>&#8211;<bold>C</bold>) High density of TILs (<italic toggle="yes">p</italic> = 0.02) and high density of TCD3<sup>+</sup> cells (<italic toggle="yes">p</italic> = 0.007) and BCD79<sup>+</sup> cells (<italic toggle="yes">p</italic> = 0.02) are associated with higher percentage of Ki-67. Bar indicates mean.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="animals-15-00287-g005.jpg"/></fig><fig position="float" id="animals-15-00287-f006" orientation="portrait"><label>Figure 6</label><caption><p>The specific survival of female dogs (<italic toggle="yes">n</italic> = 34; 22 died and 12 alive) with mammary gland neoplasms with a solid arrangement in relation to the presence of TILs, TCD3<sup>+</sup>, and BCD79<sup>+</sup> cells. Kaplan&#8211;Meier. (<bold>A</bold>) The infiltrate of peritumoral (PT) TILs; (<bold>B</bold>) the infiltrate of intratumoral (IT) TILs. (<bold>C</bold>) The infiltrate of peritumoral (PT) TCD3<sup>+</sup> cells and (<bold>D</bold>) intratumoral (IT) TCD3<sup>+</sup> cells; (<bold>E</bold>) the infiltrate of peritumoral (PT) B CD79<sup>+</sup> cells; (<bold>F</bold>) intratumoral (IT) CD79<sup>+</sup> cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="animals-15-00287-g006.jpg"/></fig><table-wrap position="float" id="animals-15-00287-t001" orientation="portrait"><object-id pub-id-type="pii">animals-15-00287-t001_Table 1</object-id><label>Table 1</label><caption><p>Counts of lymphocyte and neutrophil (H&amp;E) and CD3<sup>+</sup> and CD79<sup>+</sup> cells (immunohistochemistry) in canine mammary neoplasms with solid arrangement (<italic toggle="yes">n</italic> = 61).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">L PT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">L IT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N PT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N IT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD3<sup>+</sup> PT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD3<sup>+</sup> IT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD79<sup>+</sup> PT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD79<sup>+</sup> IT</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mean</td><td align="center" valign="middle" rowspan="1" colspan="1">305</td><td align="center" valign="middle" rowspan="1" colspan="1">185</td><td align="center" valign="middle" rowspan="1" colspan="1">13.9</td><td align="center" valign="middle" rowspan="1" colspan="1">11.0</td><td align="center" valign="middle" rowspan="1" colspan="1">258</td><td align="center" valign="middle" rowspan="1" colspan="1">302</td><td align="center" valign="middle" rowspan="1" colspan="1">122</td><td align="center" valign="middle" rowspan="1" colspan="1">84.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Median</td><td align="center" valign="middle" rowspan="1" colspan="1">221</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">202</td><td align="center" valign="middle" rowspan="1" colspan="1">215</td><td align="center" valign="middle" rowspan="1" colspan="1">73</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard deviation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">301</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">214</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">287</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130</td></tr></tbody></table><table-wrap-foot><fn><p>n: sample number; L: Lymphocytes; PT: peritumoral; IT: intratumoral.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="animals-15-00287-t002" orientation="portrait"><object-id pub-id-type="pii">animals-15-00287-t002_Table 2</object-id><label>Table 2</label><caption><p>Morphological and immunophenotypic characteristics and frequency of infiltration density of lymphocytes and neutrophils in canine mammary neoplasms with solid arrangement (<italic toggle="yes">n</italic> = 61). Fisher&#8217;s exact test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variables</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Lymphocytes </th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Neutrophils</th></tr><tr><th colspan="2" align="center" valign="middle" rowspan="1">PT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th colspan="2" align="center" valign="middle" rowspan="1">IT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th colspan="2" align="center" valign="middle" rowspan="1">PT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th colspan="2" align="center" valign="middle" rowspan="1">IT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Histhological types</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CSP</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (66.7%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (66.7%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.02 *</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (22.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (77.8%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.43</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (44.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (55.6%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.68</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SPC</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (62.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (37.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (75%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (37.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (62.5%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BC</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (57.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (78.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (21.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (47.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (52.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (63.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (36.8%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MM</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MAME</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (57.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (37.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (63.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (57.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (57.9%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Immunophenotype</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L A</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (61.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (38.5%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.47</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (30.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (69.2%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (69.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (30.8%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (61.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (38.5%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L B HER-2 -</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (47.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (52.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (54.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (45.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (47.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (52.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (50%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L B HER-2 +</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (83.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Size (T)</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1 (1&#8211;3 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (56%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (44%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (64%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (36%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.09</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (48%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (52%)</td><td rowspan="3" align="center" valign="middle" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (56%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (44%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2 (3&#8211;5 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (41.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (58.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (66.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (41.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (58.3%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3 (&gt;5 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (54.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (37.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (62.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (54.2%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Nodal Metastasis</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Present</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (66.7%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (52.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (47.6%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (28.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (71.4%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (38.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (61.9%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.28</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Absent</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (57.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (42.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (47.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (52.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (57.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (42.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (55%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (45%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cox-2</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (63.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (36.6%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (54.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (45.2%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (50%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (54.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (45.2%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.09</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (52.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (47.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (35.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (64.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (41.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (58.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (29.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (70.6%)</td></tr></tbody></table><table-wrap-foot><fn><p>PT: peritumoral; IT: intratumoral; CSP: carcinoma with solid pattern; SPC:solid papillary carcinoma; BC: basaloid carcinoma; MAME: malignant adenomyoepithelioma; MME: malignant myoepithelioma L: luminal; *statistically significant when <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="animals-15-00287-t003" orientation="portrait"><object-id pub-id-type="pii">animals-15-00287-t003_Table 3</object-id><label>Table 3</label><caption><p>Morphological and immunophenotypic characteristics and frequency of infiltration density of TCD3<sup>+</sup> and BCD79<sup>+</sup> cells in canine mammary neoplasms with solid arrangement (<italic toggle="yes">n</italic> = 61). Fisher&#8217;s exact test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variables</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Lymphocytes CD3</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Lymphocytes CD79</th></tr><tr><th colspan="2" align="center" valign="middle" rowspan="1">PT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th colspan="2" align="center" valign="middle" rowspan="1">IT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th colspan="2" align="center" valign="middle" rowspan="1">PT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th colspan="2" align="center" valign="middle" rowspan="1">IT</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Histhological types</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CSP</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (66.7%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (66.7%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.23</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (66.7%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (88.9%)</td><td rowspan="5" align="center" valign="middle" colspan="1">0.19</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SPC</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (62.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (37.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (75%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (62.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (37.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (50%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BC</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (57.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (52.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (47.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (57.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (57.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MM</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (83.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MAME</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (52.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (47.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (52.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (47.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (57.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (42.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (47.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (52.6%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Immunophenotype</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L A</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (69.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (30.8%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.28</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (76.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (23.1%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.04 *</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (53.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (46.2%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (53.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (46.2%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.71</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L B HER-2 -</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (42.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (57.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (45.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (54.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (47.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (52.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (42.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (57.1%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L B HER-2 +</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (30%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (83.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.7%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Size (T)</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1 (1&#8211;3 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (48%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (52%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (44%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (56%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.56</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (56%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (44%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (52%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (48%)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.31</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2 (3&#8211;5 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (41.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (58.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (41.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (58.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (41.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (58.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (75%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3 (&gt;5 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (54.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (58.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (41.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (54.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (54.2%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Nodal Metastasis</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Present</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (52.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (47.6%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (33.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (66.7%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (52.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (47.5%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (23.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (76.2%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.03 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Absent</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (47.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (52.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (57.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (42.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (42.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (57.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (55%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (45%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cox-2</italic>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (45.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (54.8%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (50%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (45.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (54.8%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (52.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (47.6%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (64.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (35.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (52.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (47.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (64.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (35.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (29.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (70.6%)</td></tr></tbody></table><table-wrap-foot><fn><p>PT: peritumoral; IT: intratumoral; CSP: carcinoma with solid pattern; SPC:solid papillary carcinoma; BC: basaloid carcinoma; MAME: malignant adenomyoepithelioma; MME: malignant myoepithelioma L: luminal; *statistically significant when <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="animals-15-00287-t004" orientation="portrait"><object-id pub-id-type="pii">animals-15-00287-t004_Table 4</object-id><label>Table 4</label><caption><p>The median survival time of female dogs with neoplasms with a solid arrangement and its association with the density of lymphocyte infiltrate, neutrophils, TCD3<sup>+</sup>, and TCD79<sup>+</sup> cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cell Infiltration</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Median Overall Survival (Days)</th></tr><tr><th colspan="2" align="center" valign="middle" rowspan="1">Peritumoral</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th colspan="2" align="center" valign="middle" rowspan="1">Intratumoral</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes</td><td align="center" valign="middle" rowspan="1" colspan="1">455</td><td align="center" valign="middle" rowspan="1" colspan="1">324</td><td align="center" valign="middle" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">425</td><td align="center" valign="middle" rowspan="1" colspan="1">321</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils</td><td align="center" valign="middle" rowspan="1" colspan="1">395</td><td align="center" valign="middle" rowspan="1" colspan="1">365</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">425</td><td align="center" valign="middle" rowspan="1" colspan="1">210</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD3 Lymphocytes</td><td align="center" valign="middle" rowspan="1" colspan="1">395</td><td align="center" valign="middle" rowspan="1" colspan="1">341</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" rowspan="1" colspan="1">425</td><td align="center" valign="middle" rowspan="1" colspan="1">360</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD79 Lymphocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">365</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">575</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">318</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Median specific survival (days)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes</td><td align="center" valign="middle" rowspan="1" colspan="1">670</td><td align="center" valign="middle" rowspan="1" colspan="1">720</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">------</td><td align="center" valign="middle" rowspan="1" colspan="1">395</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils</td><td align="center" valign="middle" rowspan="1" colspan="1">670</td><td align="center" valign="middle" rowspan="1" colspan="1">575</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" rowspan="1" colspan="1">1035</td><td align="center" valign="middle" rowspan="1" colspan="1">575</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD3 Lymphocytes</td><td align="center" valign="middle" rowspan="1" colspan="1">670</td><td align="center" valign="middle" rowspan="1" colspan="1">720</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">------</td><td align="center" valign="middle" rowspan="1" colspan="1">365</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD79 Lymphocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">------</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">395</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">------</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">395</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td></tr></tbody></table><table-wrap-foot><fn><p>* statistically significant when <italic toggle="yes">p</italic> &lt; 0.05. Long-rank test. ------ more than 50% of animals were still alive at the end of the study.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="animals-15-00287-t005" orientation="portrait"><object-id pub-id-type="pii">animals-15-00287-t005_Table 5</object-id><label>Table 5</label><caption><p>Univariate and multivariate analyses of specific survival (Cox model) in relation to intratumoral TIL and CD3<sup>+</sup> in female dogs with neoplasms with solid arrangement.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<italic toggle="yes">Variables</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Univariate Analyses</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Metastasis</td><td align="left" valign="middle" rowspan="1" colspan="1">Absent</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Present</td><td align="center" valign="middle" rowspan="1" colspan="1">6.54</td><td align="center" valign="middle" rowspan="1" colspan="1">2.61&#8211;16.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001 *</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IT Lymphocytes</td><td align="left" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">2.76</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08&#8211;7.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03 *</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IT CD3 Lymphocytes </td><td align="left" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19&#8211;7.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02 *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Multivariate analyses</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Metastasis</td><td align="left" valign="middle" rowspan="1" colspan="1">Absent</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Present</td><td align="center" valign="middle" rowspan="1" colspan="1">3.23</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09&#8211;9.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03 *</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IT Lymphocytes</td><td align="left" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22&#8211;2.39</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IT CD3 Lymphocytes </td><td align="left" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25&#8211;2.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td></tr></tbody></table><table-wrap-foot><fn><p>HR, hazard ratio, CI, Confidence interval, IT: intratumoral; TILs: tumor-infiltrating lymphocytes. * Statistically significant when <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>